Via Surgical
Transfascial Suture Fixation for Soft-tissue Repair
Company Overview
Snapshot
Founded in March 2012 by Arik Levy, Via Surgical operates with 1–10 employees. The company raised a total of $8.15M across 4 funding rounds from 4 investors. In October 2023, Via Surgical ceased operations.
Business overview
Via Surgical develops the FasTouch system, a transfascial suture fixation technology designed for strong, consistent, and rapid deployment in hernia repair. Its core product features lightweight, closed, locked-loop sutures that aim to reduce foreign body response and chronic pain. The company serves the medical devices industry, specifically focusing on surgical solutions for soft-tissue repair within the Health Tech & Life Sciences sector.
Strategic signal
Via Surgical ceased operations in October 2023, indicating a significant and definitive end to its business activities. This event signals to investors and innovation teams that the company is no longer an active player in the medical device market, despite its prior product development and regulatory achievements.
Log in to access full profile ›Company Intelligence Q&A
- What is the current operational status of Via Surgical?
- Via Surgical ceased to operate in October 2023, marking its status as non-active.
- What was a key regulatory achievement for Via Surgical?
- In March 2019, Via Surgical received FDA clearance for its FasTouch Absorbable Fixation System.
- Did Via Surgical secure any additional FDA clearances?
- Yes, in June 2021, Via Surgical gained 510(k) FDA clearance for its TissueTak Tendon Anchor.